StockData

Prelude Therapeutics vs Zentalis Pharmaceuticals

PRLD and ZNTL side by side, both in drugs. Figures are trailing twelve months unless noted, from SEC filings and end-of-day prices.

How PRLD and ZNTL compare

Prelude Therapeutics is the larger company, worth 2.5 times as much as Zentalis Pharmaceuticals ($265M against $107M).

Prelude Therapeutics scores higher on the StockData Score (8 against 6 for Zentalis Pharmaceuticals), which adds up 30 checks on valuation, growth, past performance, financial health and dividends.

Key numbers

A dot marks the better figure where higher or lower is clearly better.

MetricPRLDZNTL
Size and price
Market cap$265M$107M
Share price$3.32$1.49
Change, 1 year118%12.0%
Change, 5 years−76.3%−98.0%
Beta (5Y)1.445.80
Employees79106
StockData Score
Total score8 (better)6
Valuation score11
Growth score1 (better)0
Performance score1 (better)0
Health score55
Dividend score00
Valuation
P/S11.8×–
P/B2.0×0.7× (better)
FCF yield−12.6% (better)−120%
Fair value$2.14–
Margin of safety−55.2%–
Growth
Revenue growth (TTM)220%–
Profitability
Operating margin−301%–
Net margin−270%–
FCF margin−148%–
Return on equity−57.7% (better)−66.7%
Financial health
Debt / equity0.000.00
Current ratio4.074.82 (better)
Altman Z-score−2.69 (better)−8.91
Piotroski F-score3 (better)1
Dividends and buybacks
Shareholder yield0.00%0.00%
Ownership
Held by institutions62.2%66.1%
Held by insiders40.5%58.0%
Insider net buying, 12 months$25.0M (better)$12.8M
Short interest, % of float8.8%16.7%

Go deeper

For information only, not investment advice. Check the source filings before relying on any figure.